Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 2/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910125 | 0.89 | NQO1 (0.56) | SIGMAR1NQO1MAPTLMNAACACB | |
| SCHEMBL12377087 | 0.86 | L3MBTL1 (0.57) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL4248652 | 0.84 | NQO1 (0.67) | SIGMAR1KMT2AMEN1NQO1L3MBTL1 | |
| SCHEMBL10575040 | 0.82 | NQO1 (0.64) | SIGMAR1KMT2AMEN1NQO1L3MBTL1 | |
| SCHEMBL14178223 | 0.82 | MEN1 (0.74) | SIGMAR1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL4615272 | 0.81 | CALM1 (0.58) | SIGMAR1KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL8986190 | 0.81 | L3MBTL1 (0.55) | SIGMAR1KMT2AMEN1L3MBTL1HTR1B | |
| SCHEMBL9523628 | 0.81 | DRD2 (0.68) | SIGMAR1KMT2AMAPTLMNAGAA | |
| SCHEMBL8986268 | 0.80 | NQO1 (0.61) | SIGMAR1KMT2AMEN1NQO1L3MBTL1 | |
| SCHEMBL14855263 | 0.80 | CHRM2 (0.57) | KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042355-B1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |